Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
MS Research Roundup: May 16, 2014
Episode 46 with Dr. Hans Lassmann on biomarkers in NMO and MS
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Episode 48 with Dr. Bruce Cree on the EPIC, CLIMB, and SUMMIT clinical studies
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
Episode 52 with Dr. David Tabby on migraines in MS
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
MS Research Roundup: July 18, 2014
Primary progressive multiple sclerosis-why we are failing.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Viral triggers of multiple sclerosis.
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
BIIB033 single ascending dose study in healthy volunteer subjects
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
ACTRIMS-ECTRIMS 2014 -- Day 3, afternoon
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
American Society for Neurochemistry 46th Annual Meeting
Gender as risk factor for autoimmune diseases.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
Episode 55 with Dr. Michael Levy on the status of regenerative stem cell therapies for multiple sclerosis
ACTRIMS-ECTRIMS 2014 -- Day 2, afternoon
Pages
« first
‹ previous
…
45
46
47
48
49
50
51
52
53
…
next ›
last »
